Metastatic castration-resistant prostate cancer: time for innovation.

about

Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

P2860

Q39031750-0F70BB21-65BD-4631-999B-90515561F91D Q58698705-F700404D-8420-46D1-BEF1-60C089B25469

P2860

Metastatic castration-resistant prostate cancer: time for innovation.

Item

http://www.wikidata.org/entity/Q38312041

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Metastatic castration-resistant prostate cancer: time for innovation.

@en

type

Item

label

Metastatic castration-resistant prostate cancer: time for innovation.

@en

prefLabel

Metastatic castration-resistant prostate cancer: time for innovation.

@en

P1476

Metastatic castration-resistant prostate cancer: time for innovation.

@en

P2093

Francesca Vignani

http://www.w3.org/2001/XMLSchema#string

Giorgio Vittorio Scagliotti

http://www.w3.org/2001/XMLSchema#string

Marcello Tucci

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Molecular determinants of resistance to antiandrogen therapy

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

P304

91-106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.145

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25572785

http://www.w3.org/2001/XMLSchema#string

Metastatic castration-resistant prostate cancer: time for innovation.

about

P2860

P2860

Metastatic castration-resistant prostate cancer: time for innovation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698